Skip to main content

Table 1 Characteristics of the all study patients.(n = 1410)

From: Intravenous iron supplementation does not increase infectious disease risk in hemodialysis patients: a nationwide cohort-based case-crossover study

Characteristics

Number of Patients (%)

Age, year

 18–35

25 (1.8)

 35–45

64 (4.5)

 45–55

223 (15.8)

 55–65

328 (23.3)

 65–75

434 (30.8)

  > 75

336 (23.8)

Mean Age (standard deviation)

65.09 (12.65)

Female

780 (55.3%)

Iron dosage during treatment

 0 mg/month

1127 (79.9)

 0-300 mg/month

162 (11.5)

 300-400 mg/month

31 (2.2)

  > 400 mg/month

90 (6.4)

Mean Iron treatment duration, months/year

(standard deviation)a

3.09 (2.17)

Permanent venous catheter on index day

49 (3.5)

Comorbidities within 2 years before index date

 Hypertension

1142 (81.0)

 Ischemic heart disease

690 (48.9)

 Stroke

278 (19.7)

 Diabetes mellitus

849 (60.2)

 Chronic pulmonary disease

317 (22.5)

 Heart failure

437 (31.0)

 Liver cirrhosis

102 (7.2)

 Connective tissue disease

215 (15.2)

 Malignancy

244 (17.3)

 Polycystic kidney disease

13 (0.9)

  1. apatients without intravenous iron treatment were excluded